Please login to the form below

Not currently logged in
Email:
Password:

liver cancer

This page shows the latest liver cancer news and features for those working in and with pharma, biotech and healthcare.

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

Gilead and Novo Nordisk boost NASH partnership with new mid-stage study

If left untreated, individuals living with NASH may face serious consequences, including end-stage liver disease, liver cancer and the need for liver transplantation. ... This study is the latest example of our persistent focus on driving innovation to

Latest news

  • Gilead set to acquire hepatitis specialist MYR for €1.15bn Gilead set to acquire hepatitis specialist MYR for €1.15bn

    Patients with HDV co-infection are at a higher risk of developing serious liver disease compared to those living with HBV infection alone. ... Those with HDV may also experience faster progression to liver fibrosis, cirrhosis, hepatic decompensation and

  • GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2 GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2

    Although hepatitis C has an effective range of treatments which can effectively cure most patients, hepatitis B remains difficult to treat and can cause cirrhosis, liver failure and liver cancer. ... Chronic hepatitis B affects around 260 million people

  • AZ’s Imfinzi plus tremelimumab combo misses again AZ’s Imfinzi plus tremelimumab combo misses again

    AZ notes the CTLA4 inhibitor remains in clinical trials in combination with Imfinzi in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer. ... $1.5bn thanks largely to wider use in NSCLC as well as bladder cancer.

  • Lilly posts higher-than-expected profit as new drugs lift outlook Lilly posts higher-than-expected profit as new drugs lift outlook

    Lilly’s dependence on Loxo’s pipeline will grow, given the fact that the company has halted development of three experimental cancer drugs. ... This includes TGF-beta R1 kinase inhibitor galunisertib, which had been in trial in lung and liver cancer.

  • Roche files Tecentriq/Avastin combo in liver cancer Roche files Tecentriq/Avastin combo in liver cancer

    Levi Garraway. “Liver cancer is the most rapidly increasing cause of cancer-related death in the US. ... The filing in liver cancer is an important milestone in Roche’s plans for Tecentriq, which is a latecomer to the checkpoint inhibitor category.

More from news
Approximately 14 fully matching, plus 125 partially matching documents found.

Latest Intelligence

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... a terminal disease, and more towards helping cancer patients manage their condition effectively.

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver). ... of this cancer.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Co-development was another area in which major pharma firms were active, particularly Lilly, which enlarged its work with Boehringer Ingelheim to add in breast cancer programmes and closed a ... NASH and biosimilars. One therapeutic indication that could

  • Pharma deals in April 2015 Pharma deals in April 2015

    The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid. ... Menarini AP will be responsible for the clinical development, regulatory approval and commercialisation of resminostat in all oncological

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics